FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253242528> ?p ?o ?g. }

• W4253242528 endingPage "2823" @default.
• W4253242528 startingPage "2817" @default.
• W4253242528 abstract "6-Mercaptopurine (6MP) and methotrexate are the backbone of continuation therapy for childhood acute lymphoblastic leukemia (ALL). In studies of oral 6MP and methotrexate, indices of chronic systemic exposure to active metabolites of these agents, namely, red blood cell (RBC) concentrations of methotrexate polyglutamates (MTXPGs) and thioguanine nucleotides (TGNs) have positively correlated with event-free survival (EFS). Our objective was to evaluate whether MTXPGs, TGNs, and the dose intensity of administered methotrexate and 6MP were prognostic in the setting of a treatment protocol in which all treatment was coordinated through a single center, and the weekly doses of methotrexate were given parenterally. On protocol Total XII, 182 children achieved remission and received weekly methotrexate 40 mg/m2 parenterally and daily oral 6MP, interrupted every 6 weeks during the first year by pulse chemotherapy. A total of 709 TGN, 418 MTX-PG, and 267 thiopurine methyltransferase (TPMT) measurements, along with complete dose intensity information (dose received divided by protocol dose per week) for 19,046 weeks of 6MP and methotrexate, were analyzed. In univariate analyses, only higher dose intensity of 6MP and of weekly methotrexate were significant predictors of overall EFS (P = .006 and .039, respectively). The occurrence of neutropenia was associated with worse outcome (P = .040). In a multivariate analysis, only higher dose intensity of 6MP (P = .020) was a significant predictor of EFS, with lower TPMT activity (P = .096) tending to associate with better outcome. 6MP dose intensity was also associated (P = .007) with EFS among patients with homozygous wild-type TPMT phenotype. Lower 6MP dose intensity was primarily due to missed weeks of therapy and not to reductions in daily dose. We conclude that increased dose-intensity of oral 6MP is an important determinant of EFS in ALL, particularly among those children with a homozygous wild-type TPMT phenotype. However, increasing intensity of therapy such that neutropenia precludes chemotherapy administration may be counterproductive." @default.
• W4253242528 created "2022-05-12" @default.
• W4253242528 creator A5009866488 @default.
• W4253242528 creator A5018363328 @default.
• W4253242528 creator A5024937927 @default.
• W4253242528 creator A5034189317 @default.
• W4253242528 creator A5076645797 @default.
• W4253242528 date "1999-05-01" @default.
• W4253242528 modified "2023-10-06" @default.
• W4253242528 title "Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia" @default.
• W4253242528 cites W1977696203 @default.
• W4253242528 cites W1996409190 @default.
• W4253242528 cites W2034207079 @default.
• W4253242528 cites W2036293356 @default.
• W4253242528 cites W2043394791 @default.
• W4253242528 cites W2047065011 @default.
• W4253242528 cites W2058710761 @default.
• W4253242528 cites W2065615362 @default.
• W4253242528 cites W2069546278 @default.
• W4253242528 cites W2079608086 @default.
• W4253242528 cites W2084912316 @default.
• W4253242528 cites W2089806240 @default.
• W4253242528 cites W2091146948 @default.
• W4253242528 cites W2093793436 @default.
• W4253242528 cites W2127625989 @default.
• W4253242528 cites W2134190122 @default.
• W4253242528 cites W2156950528 @default.
• W4253242528 cites W2173315827 @default.
• W4253242528 cites W2319249430 @default.
• W4253242528 doi "https://doi.org/10.1182/blood.v93.9.2817.409k04_2817_2823" @default.
• W4253242528 hasPublicationYear "1999" @default.
• W4253242528 type Work @default.
• W4253242528 citedByCount "30" @default.
• W4253242528 countsByYear W42532425282013 @default.
• W4253242528 countsByYear W42532425282014 @default.
• W4253242528 countsByYear W42532425282016 @default.
• W4253242528 countsByYear W42532425282017 @default.
• W4253242528 countsByYear W42532425282018 @default.
• W4253242528 countsByYear W42532425282019 @default.
• W4253242528 countsByYear W42532425282020 @default.
• W4253242528 countsByYear W42532425282021 @default.
• W4253242528 countsByYear W42532425282022 @default.
• W4253242528 crossrefType "journal-article" @default.
• W4253242528 hasAuthorship W4253242528A5009866488 @default.
• W4253242528 hasAuthorship W4253242528A5018363328 @default.
• W4253242528 hasAuthorship W4253242528A5024937927 @default.
• W4253242528 hasAuthorship W4253242528A5034189317 @default.
• W4253242528 hasAuthorship W4253242528A5076645797 @default.
• W4253242528 hasConcept C126322002 @default.
• W4253242528 hasConcept C2776694085 @default.
• W4253242528 hasConcept C2776760755 @default.
• W4253242528 hasConcept C2777063308 @default.
• W4253242528 hasConcept C2777173762 @default.
• W4253242528 hasConcept C2778461978 @default.
• W4253242528 hasConcept C2779134260 @default.
• W4253242528 hasConcept C2781059491 @default.
• W4253242528 hasConcept C2781107101 @default.
• W4253242528 hasConcept C2909962599 @default.
• W4253242528 hasConcept C70917649 @default.
• W4253242528 hasConcept C71924100 @default.
• W4253242528 hasConcept C90924648 @default.
• W4253242528 hasConcept C98274493 @default.
• W4253242528 hasConceptScore W4253242528C126322002 @default.
• W4253242528 hasConceptScore W4253242528C2776694085 @default.
• W4253242528 hasConceptScore W4253242528C2776760755 @default.
• W4253242528 hasConceptScore W4253242528C2777063308 @default.
• W4253242528 hasConceptScore W4253242528C2777173762 @default.
• W4253242528 hasConceptScore W4253242528C2778461978 @default.
• W4253242528 hasConceptScore W4253242528C2779134260 @default.
• W4253242528 hasConceptScore W4253242528C2781059491 @default.
• W4253242528 hasConceptScore W4253242528C2781107101 @default.
• W4253242528 hasConceptScore W4253242528C2909962599 @default.
• W4253242528 hasConceptScore W4253242528C70917649 @default.
• W4253242528 hasConceptScore W4253242528C71924100 @default.
• W4253242528 hasConceptScore W4253242528C90924648 @default.
• W4253242528 hasConceptScore W4253242528C98274493 @default.
• W4253242528 hasIssue "9" @default.
• W4253242528 hasLocation W42532425281 @default.
• W4253242528 hasOpenAccess W4253242528 @default.
• W4253242528 hasPrimaryLocation W42532425281 @default.
• W4253242528 hasRelatedWork W1256525631 @default.
• W4253242528 hasRelatedWork W2001609557 @default.
• W4253242528 hasRelatedWork W2047065011 @default.
• W4253242528 hasRelatedWork W2067974345 @default.
• W4253242528 hasRelatedWork W2070843022 @default.
• W4253242528 hasRelatedWork W2955773501 @default.
• W4253242528 hasRelatedWork W3013915831 @default.
• W4253242528 hasRelatedWork W3165742733 @default.
• W4253242528 hasRelatedWork W4242566368 @default.
• W4253242528 hasRelatedWork W4253242528 @default.
• W4253242528 hasVolume "93" @default.
• W4253242528 isParatext "false" @default.
• W4253242528 isRetracted "false" @default.
• W4253242528 workType "article" @default.